Get the Stockscreener App
9.23
3.15%
-0.30
Pre-market:
9.38
0.15
+1.63%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $9.23, with a volume of 25.29M.
It is down -3.15% in the last 24 hours and down -18.17% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$9.53
Open:
$9.63
24h Volume:
25.29M
Relative Volume:
2.70
Market Cap:
$11.02B
Revenue:
$15.05B
Net Income/Loss:
$-883.30M
P/E Ratio:
-12.47
EPS:
-0.74
Net Cash Flow:
$1.89B
1W Performance:
-17.96%
1M Performance:
-18.17%
6M Performance:
-23.59%
1Y Performance:
-25.38%
1-Day Range:
$9.10
$9.72
1-Week Range:
$8.7701
$11.53
52-Week Range:
$8.7701
$13.55
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
9.23 | 11.02B | 15.05B | -883.30M | 1.89B | -0.74 |
|
ZTS
Zoetis Inc
|
167.24 | 74.89B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.18 | 46.03B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.41 | 45.69B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.46 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.20 | 13.63B | 612.78M | -86.37M | -62.91M | -0.87 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris outlines $450M-$550M product revenue target for 2025 while addressing Indore impact - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Viatris Inc. (VTRS) Investors to Inquire about Securities Investigation - Markets Insider
Tesla, Palantir And MicroStrategy Are Among Top 12 Large-Cap Losers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio? - Benzinga
Is Viatris Inc. (VTRS) the Best Weight Loss Drug Stock to Buy According to Analysts? - Insider Monkey
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris - GlobeNewswire
Here's What Key Metrics Tell Us About Viatris (VTRS) Q4 Earnings - Nasdaq
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Stock Of The Day: Why The Viatris Meltdown Ended Where It Did - Benzinga
Lost Money on Viatris Inc. (VTRS)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Viatris Inc. (VTRS) And Encourages Investors to Reach Out - Markets Insider
Barclays Adjusts Price Target on Viatris to $9 From $12, Keeps Underweight Rating - Marketscreener.com
Why Viatris Inc. (VTRS) Went Down on Thursday - MSN
Viatris Rocked By Indore US Block, With $500m Revenue Sting Anticipated In 2025 - Insights
Viatris Inc. (NASDAQ:VTRS) Q4 2024 Earnings Call Transcript - Insider Monkey
Viatris Inc.: A Comprehensive Analysis of Financial Performance, Strategic Initiatives, and Market Challenges - HPBL
Viatris plummets sharply on disappointing fourth-quarter, 2025 outlook - Investing.com
Nxera Pharma clinches millions from autoimmune disease deal - Business Weekly
Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale - ACCESS Newswire
Viatris: Q4 Earnings Snapshot - Thehour.com
Viatris Reports Strong 2024 Financial Results - TipRanks
Viatris, Inc. Earnings Call: Balancing Growth and Challenges - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Viatris Inc. (VTRS) And Encourages Stockholders to Reach Out - Markets Insider
Nxera Pharma Assigns Cenerimod Rights to Viatris for Japan and APAC - TipRanks
Viatris Inc. stock falls Thursday, underperforms market - MSN
Viatris' 2025 Looks Shaky From Site Inspection but Future Launches and Pipeline Support Our Outlook - Morningstar
Viatris Inc SEC 10-K Report - TradingView
Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges - MSN
Viatris Inc to Host Earnings Call - ACCESS Newswire
Viatris Stock Tumbles On Q4 Earnings Miss, FDA Warning Clouds 2025 Outlook - Benzinga
Viatris Shares Drop After Q4 Results Miss Consensus -February 27, 2025 at 12:49 pm EST - Marketscreener.com
Viatris launches global review, plans aggressive share buybacks - The Business Journals
Viatris is Oversold - Nasdaq
Drugmaker Viatris forecasts weak 2025 results after import curbs on India plant -February 27, 2025 at 11:15 am EST - Marketscreener.com
Drugmaker Viatris forecasts weak 2025 results after import curbs on India plant - Reuters
Viatris: One Swallow Doesn't Make A Summer (NASDAQ:VTRS) - Seeking Alpha
Viatris plummets sharply on disappointing fourth-quarter, 2025 outlook By Investing.com - Investing.com Australia
Earnings call transcript: Viatris Inc Q4 2024 misses EPS estimates, stock dives - Investing.com
Is Viatris Inc. (VTRS) the Best Low Price Pharma Stock to Invest In Right Now? - Insider Monkey
Viatris slides as FDA scrutiny on India plant clouds outlook - MSN
Drugmaker Viatris forecasts weak 2025 results after import curbs on India plant -February 27, 2025 at 08:18 am EST - Marketscreener.com
Viatris stock slides after Q4 2024 miss (VTRS:NASDAQ) - Seeking Alpha
Viatris (VTRS) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance
Viatris Inc. Announces Quarterly Dividend, Payable on March 18, 2025 -February 27, 2025 at 06:30 am EST - Marketscreener.com
Viatris' Q4 Adjusted Earnings, Revenue Fall; Provides 2025 Guidance -February 27, 2025 at 07:20 am EST - Marketscreener.com
Viatris shares tumble over 5% as Q4 results miss estimates, 2025 outlook disappoints - Investing.com
Earnings Flash (VTRS) VIATRIS INC. Posts Q4 Adjusted EPS $0.54, vs. FactSet Est of $0.56 - Marketscreener.com
(VTRS) VIATRIS INC. Expects Fiscal Year 2025 Adjusted EPS Range $2.12$2.26 - Marketscreener.com
Earnings Flash (VTRS) VIATRIS INC. Posts Q4 Revenue $3.53B, vs. FactSet Est of $3.59B - Marketscreener.com
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):